Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively "DAWA"
Terminated
Phase 2/3 ResultsSummary of Purpose
DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus. There are no formal primary or secondary clinical efficacy or safety outcomes because it is a pilot study. Trial Stopped: because a significant decrease of viable candidates for the study.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 14 September 2015.
1 Aug 2013 | 28 May 2013 | 1 Sep 2014 | 1 Oct 2014 | 1 Sep 2015 | 24 Jun 2015 |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
- Andre R Duraes, PhD
andreduraes@gmail.com 0557191888399
View Trial Locations
Recruitment
- Enrollment: 27
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- Andre R Duraes, Professor
Hospital Ana Nery